AuthentiKine™ Human IFN-beta ELISA Kit0 Publications

Catalog number: KE00195





Images See all


Product name:
AuthentiKine™ Human IFN-beta ELISA Kit

1 X 96 well plate

Sample type:
Serum, Plasma, Cell culture supernatants

Assay type:

0.76 pg/ml

7.8-500 pg/mL

Reacted Species:

Tested applications:
Sandwich ELISA

Sample TypeAverageRange
Human Plasma 89 72-107
Cell culture supernatants 84 78-96

Samplenmean (pg/ml)SDCV%
1 20 244.5 5.2 2.1
2 20 61.6 1.7 2.8
3 20 14.9 1.3 8.8

Samplenmean (pg/ml)SDCV%
1 24 244.7 6.3 2.6
2 24 64.5 2.0 3.1
3 24 16.5 1.6 9.6

Product overview:
KE00195 is a solid phase sandwich Enzyme Linked-Immuno-Sorbent Assay (Sandwich ELISA). The IFN-beta ELISA kit is to be used to detect and quantify protein levels of endogenous IFN-beta. The assay recognizes human IFN-beta. An antibody specific for IFN-beta has been pre-coated onto the microwells. The IFN-beta protein in samples is captured by the coated antibody after incubation. Following extensive washing, another antibody specific for IFN-beta is added to detect the captured IFN-beta protein. For signal development, horseradish peroxidase (HRP)-conjugated antibody is added, followed by Tetramethyl-benzidine (TMB) reagent. Solution containing sulfuric acid is used to stop color development and the color intensity which is proportional to the quantity of bound protein is measurable at 450 nm with the correction wavelength set at 630 nm.


Storage Instructions:
All the reagents are stored at 2-8℃ for 6 months or -20℃ for 12 months. Refer to the protocol for further storage instructions.

Fibroblast interferon, IFB, IFF, IFN beta, IFNB, IFNB1, IFN-beta, IFNβ, IFN-β, Interferon beta, interferon, beta 1, fibroblast

Interferon beta (IFN-beta) is a cytokine that is naturally produced by the immune system in response to biological and chemical stimuli. It signals by binding to the heterodimeric type I IFN receptor composed of the IFNAR1 and IFNAR2 chains, and regulates the expression of a plethora of genes by means of the classical JAK/STAT and other pathways. Interferon beta (IFN-beta) has been shown in several clinical trials to have efficacy in multiple sclerosis. Interferon beta gene therapy is expected to become widely available for clinical use in cancer patients, and this new strategy might be extended to molecular targeting therapy, or used in combination with cell therapy or other therapies.

to top